TKIs such as imatinib mesylate (Gleevec® Novartis, Basilea, Switzerland), nilotinib (Tasigna®, c Novartis, Basilea, Switzerland), and dasatinib (Sprycel® Bristol-Myers Squibb, New York, NY, USA) are used as the front-line therapy in Ph+CML and Ph+ALL; only Imatinib has also been approved for the first-line therapy of GIST, characterized by c-KIT and PDGFRA mutations [127,128], renal cell carcinoma (RCC) and epidermal growth factor receptor (EGFR) mutation-positive non small cell lung cancer (NSCLC) [129,130]. Here, PDGFRA is linked to renal cell carcinoma.